Increased levels of human cysteine proteases have been implicated in the progression of tumors from the premalignant to the malignant state. The physiological activities of these proteases are regulated by their interactions with specific inhibitors. To our knowledge there have been no previous reports about the cysteine protease inhibitors (CPIs) in human brain tumors. In the study reported here, we determined CPI activity during glioma progression and compared that with normal human brain tissue. We also determined CPI activities in meningioma and glioblastoma cell lines in vitro. This activity was significantly higher in normal brain tissue and low-grade glioma than in anaplastic astrocytoma and glioblastoma. CPI activity was significantly higher in benign and atypical meningioma cell extracts in comparison with those from malignant meningiomas and with those from glioblastoma cell lines. After several passages, one benign meningioma cell line showed reduced levels of CPI and increased levels of cathepsin. Our results suggest that decreases in the activities of CPI may contribute to the malignant properties of brain tumors.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Jaaskelainen J, Halta M and Servo A, 1986, Atypical and anaplastic meningiomas: radiology, surgery, radiotherapy, and outcome. Surg Neurol, 25, 233–42.
Wilson CB, 1995, Meningiomas: genetics, malignancy and the role of irradiation in their induction and treatment. Schneider Lecture, presented at the American Association of Neurological Surgeons Meeting, San Francisco, 1992.
Sivaparvathi M, Sawaya R, Wang SWet al. 1995, Overexpression and localization of cathepsin B during the progression of human gliomas. Clin Exp Metastasis, 13, 49–56.
Barrett An, 1987, The cystatins: a new class of peptidase inhibitors. Trends Biochem Sci, 12, 193–6.
Lenarcic B, Krasovec M, Ritonja A, Olafsson I and Turk V, 1991, Inactivation of human cystatin C and kiminogen by human cathepsin D. FEBS Lett, 280, 211–15.
Lenarcic B, Kos J, Dolenc I, Lucovnik P, Krizaj I and Turk V, 1988, Cathepsin D inactivates cysteine protease inhibitors cystatins. Biochem Biophys Res Commun, 154, 765–72.
Okamoto H and Greenbaum LM, 1983, Isolation and structure of T-Kinin. Biocehm Biophys Res Commun, 112, 701–7083.
Abrahamson M, Mason RW, Hansson H, Buttle DJ, Grubb A and Ohlsson K, 1991, Human cystatin C role of the N-terminal segment in the inhibition of human cysteine proteinases and in its activation by leucocyte elastase. Biochem J, 273, 621–6.
Moin K, Emmert LT and Sloane BF, 1992, A membrane associated cysteine protease inhibitor from murine hepatoma. FEBS Lett, 309, 279–82.
Barrett, AJ, Davies ME and Grubb A, 1984, The place of human y-trace (cystatin C) amongst the cysteine protease inhibitors. Biochem Biophys Res Commun, 120, 631–6.
Abrahamson M, Barrett AJ, Salvesen G and Grubb A, 1986, Isolation of six cysteine protease inhibitors from human urine. J Biol Chem, 261, 11282–9.
Salvesen G, Parkes C, Abrahamson M, Grubb A and Barrett AJ, 1986, Human low Mr kininogen contains three copies of a cystatine sequence that are divergent in structure and in inhibitory activity for cysteine proteinases. Biochem J, 234, 429–34.
Jarvinen M, Rinnee A and Hopsu-Havu VK, 1987, Human cystatine in normal and diseased tissues: a review. Acta Histochem, 82, 5–18.
Hara K, Kominami E and Katunuma N, 1988, Effect of proteinase inhibitors on intracellular processing of cathepsin B, H and L in rat macrophages. FEBS Lett, 231, 229–31.
Chambers AF, Colella R, Denhardt DT and Wilson SM, 1992, Increased expression of cathepsins L and B, and decreased activity of their inhibitors, in metastatic, ras-transformed NIH 3T3 cells. Mol Carcinogen, 5, 238–45.
McCormick D, 1993, Secretion of cathepsin B by human gliomas in vitro. Neuropathol Appl Neurobiol, 19, 146–51.
Bradford MM, 1976, A rapid and sensitive method for the quantitations of microgram quantities of protein utilizing the principle of protein dye binding. Anal Biochem, 72, 248–54.
Rozhin J, Wade RL, Honn KV and Sloane BF, 1989, Membrane-associated cathepsin L: a role in metastasis of melanomas. Biochem Biophys Res Commun, 164, 556–61.
Moin K, Emmert LT and Sloane BF, 1992, A membrane associated cysteine protease inhibitor from murine hepatoma. FEBS Lett, 309, 279–82.
Barrett AJ and Kirschke H, 1981, Cathepsin B, cathepsin H and cathepsin L. Meth Enzymol, 80, 535–61.
Kirschke H and Shaw E, 1981, Rapid inactivation of cathepsin L by Z-Phe-Phe-CHN2 and Z-Phe-AlaCHN2. Biochem Biophys Res Commun, 101, 454–8.
Sloane BF, Moin K, Krepela E and Rozhin J, 1990, Cathepsin B and its endogenous inhibitors: the role in tumor malignancy. Cancer Metastasis Rev, 9, 333–52.
Denhardt DT, Greenberg AH, Egan SE, Hamilton RT and Wright JA, 1987, Cysteine proteinase cathepsin L expression correlates closely with the metastatic potential of H-ras-transformed murine fibroblasts. Oncogene, 2, 55–9.
Chauhan SS, Goldstein LJ and Gottesman MM, 1991, Expression of cathepsin L in human tumors. Cancer Res, 51, 1478–81.
Sivaparvathi M, Yamamoto M, Nicolson GL, et al. 1996, Expression and immunohistochemical localization of cathepsin L during the progression of human gliomas. Clin Exp Metastasis, 14, 27–34.
Baricos WH, Zhou Y, Mason RW and Barrett AJ, 1988, Human kidney cathepsin B and L: characterization and potential role in degradation of glomerular basement membrane. Biochem J, 252, 301–4.
Rozhin J, Gomez AP, Ziegler GH, et al. 1990, Cathepsin B to cysteine proteinase inhibitor balance in metastatic cell subpopulations isolated from murine tumors. Cancer Res, 50, 6278–84.
Hawley-Nelson p, Roop DR, Cheng CK, Krieg TM and Yuspa SH, 1988, Molecular cloning of mouse epidermal cystatin A and detection of regulated expression in differentiation and tumorigenesis. Mol Carcino, 1, 202–11.
Ponton A, Coulombe B and Skup D, 1991, Decreased expression of tissue inhibitor of metalloproteinases in metastatic tumor cells leading to increased levels of collagenase activity. Cancer Res, 51, 2138–43.
Rao JS, Steck PA, Mohanam S, Stetler-Stevenson WG, Liotta LA and Sawaya R, 1993, Elevated levels of Mr 92,000 type IV collagenase in human brain tumors. Cancer Res, 53, 2208–11.
Mohanam S, Wang SW, Rayford A, et al. 1995, Expression of tissue inhibitors of metalloproteinases negative regulators of human glioblastomas invasion in vivo. Clin Exp Metastasis, 13, 57–62.
Pagano M, Capony F and Rochefort H, 1990, In vitro activation of pro-Cathepsin B by Cathepsin D, both secreted by breast cancer cells. Cr Acad Sci Paris 309, 7–12.
Montcourrier P, Mangeat PH, Salazar G, Morisset M, Sahuquet A and Rochefort H, 1990, Cathepsin D in breast cancer cells can digest extracellular matrix in large acid vesicles. Cancer Res, 50, 6045–54.
Monsky WL and Chen W-T, 1993, Proteases of cell adhesion proteins in cancer. Sem Cancer Biol, 4, 251–8.
Sun Q, 1989, Growth stimulation of 3T3 fibroblasts by cystatin. Exp Cell Res, 80, 150–60.
Hiwasa T, Sawada T and Sakiyama S, 1990, Cysteine protease inhibitors and ras gene products share the same biological activities including transforming activity toward NlH/3T3 mouse fibroblasts and the differentiation-inducing activity toward PC12 rat pheochromocytoma cells. Carcinogenesis, 11, 75–80.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sivaparvathi, M., McCutcheon, I., Sawaya, R. et al. Expression of cysteine protease inhibitors in human gliomas and meningiomas. Clin Exp Metast 14, 344–350 (1996). https://doi.org/10.1007/BF00123393
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00123393